Alkem Laboratories Ltd
Alkem Laboratories Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Alkem estimates sales of INR 600 crores in calendar year 2026 from key products, targeting a 14% CAGR over the next 5 years excluding new product launches. Alkem anticipates growing its MedTech segment revenues to around INR 1,000 crores in 3-5 years with EBITDA margins improving to 20-25%.
From Alkem Laboratories Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Alkem estimates sales of INR 600 crores in calendar year 2026 from key products, targeting a 14% CAGR over the next 5 years excluding new product launches. (Page 13)
- Growth drivers include newer products awaiting regulatory approvals (e.g., PFO in the US with high ASP of $9,500), geographic expansion into emerging markets, and deeper market penetration where current presence is low. (Pages 12-13)
- MedTech business revenue expected to reach around INR 1,000 crores in 3-5 years with EBITDA margin improving towards 20-25%. (Page 5)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Alkem Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Initial investment of around INR 1,100 crores planned for Occlutech acquisition.
- Additional INR 100-200 crores earmarked over 2 years to accelerate R&D programs, including new product launches like LA in Europe.
- MedTech incremental investment expected at INR 200-300 crores over the next 3-4 years, with most significant investment already done.
- Plans to invest further in launching new products (e.g., PFO launch in the U.S. by June 2027) with most R&D spend already completed.
- Refinancing of high-interest debt for Occlutech planned to reduce interest cost from 10% to 5-6%.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alkem Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Alkem Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹3.6K Cr, net profit ₹251 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alkem Lab's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
- Mankind Pharma (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
- Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
- Shilpa Medicare Ltd (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…
Frequently Asked Questions
What were Alkem Laboratories Ltd Q3 FY26 results?
Alkem estimates sales of INR 600 crores in calendar year 2026 from key products, targeting a 14% CAGR over the next 5 years excluding new product launches. Alkem anticipates growing its MedTech segment revenues to around INR 1,000 crores in 3-5 years with EBITDA margins improving to 20-25%.
What is Alkem Laboratories Ltd share price analysis?
Alkem Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 27.9 with a market cap of ₹68,110 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alkem Laboratories Ltd planning capital expenditure?
Initial investment of around INR 1,100 crores planned for Occlutech acquisition. - Additional INR 100-200 crores earmarked over 2 years to accelerate R&D programs, including new product launches like LA in Europe. - MedTech incremental investment expected at INR 200-300 crores over the next 3-4 years, with most significant investment already done. - Plans to invest further in launching new products (e.g., PFO launch in the U.S.
Keep Alkem Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.